Allergan Inc, a global healthcare company with a Canadian head office in Markham, recently got approval from Health Canada for its eye medication
Restasis, which the company claims is the "first prescription eye drop to target the underlying causes of chronic Dry Eye."
University of Ottawa opthamology professor Dr. Bruce Jackson explains that the condition can cause reduced vision and impair such tasks as driving. "By increasing tear production, Restasis is the first approved drug that targets the underlying causes of Dry Eye," which, he says, can improve quality of life for patients.
Allergan has been in the eye care business internationally for over 60 years, though it has since branched out into other specialties including neurosciences and obesity. It's Canadian operation currently employs 170 people and is currently
hiring five more in the GTA.
Writer: Edward Keenan
Source: Amanda Mills Sirois, Allergan Inc.